Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures

Mariano Bizzarri, Alessandra Cucina, Maria Giovanna Valente, Fausto Tagliaferri, Valeria Borrelli, Francesco Stipa, Antonino Cavallaro

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Background. Evidence has accumulated that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is involved in the regulation of the proliferation of breast tumor cells. For complete tumor suppression high hypercalcemic doses of 1,25-(OH)2D3 are needed. The aim of this study was to assess the effect of combined treatment of 1,25-(OH)2D3 at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4. Materials and methods. RM4 cell proliferation was assessed by [3H]thymidine uptake. The presence of TGF-β1 in serum-free conditioned medium was determined by inhibition antibody binding assay. Results. In 17-βE cultured RM4 cells both MEL and 1,25-(OH)2D3 alone and in combination significantly reduced [3H]thymidine incorporation in a dose-related fashion. MEL by itself was ineffective in inhibiting the FCS-cultured RM4 cells, while 1,25-(OH)2D3 strongly inhibited [3H]thymidine incorporation. Meanwhile, MEL increased the sensitivity of the FCS-cultured RM4 cells to 1,25-(OH)2D3 in the combined regimen, from 20- to 100-fold. MEL significantly enhanced the TGF-β1 secretion from RM4 cells and vitamin D3 increased the TGF-β1 secretion in a dose-dependent manner, from 2- to 7-fold. Moreover, a further enhancement of the TGF-β1 release was obtained with the combined treatment, but only for low 1,25-(OH)2D3 concentrations. The addition of monoclonal anti-TGF-β1 antibody to the medium of RM4 cells exposed to vitamin D3 alone or in combination with MEL increased the [3H]thymidine uptake compared to the correspondent cells cultured without antibody. Conclusions. Our data point to a potential benefit of combination therapy with 1,25-(OH)2D3 and MEL in the treatment of breast cancer and suggest that the growth inhibition could be related, at least in part, to the enhanced TGF-β1 secretion.

Original languageEnglish
Pages (from-to)332-337
Number of pages6
JournalJournal of Surgical Research
Volume110
Issue number2
DOIs
Publication statusPublished - Apr 2003

Fingerprint

Cholecalciferol
Melatonin
Cell Culture Techniques
Breast Neoplasms
Thymidine
Growth
Cultured Cells
Antibodies
Calcitriol
Serum-Free Culture Media
Conditioned Culture Medium
Estrogens
Cell Proliferation
Cell Line
Neoplasms

Keywords

  • Breast cancer
  • Melatonin
  • TGF-β
  • Vitamin D

ASJC Scopus subject areas

  • Surgery

Cite this

Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures. / Bizzarri, Mariano; Cucina, Alessandra; Valente, Maria Giovanna; Tagliaferri, Fausto; Borrelli, Valeria; Stipa, Francesco; Cavallaro, Antonino.

In: Journal of Surgical Research, Vol. 110, No. 2, 04.2003, p. 332-337.

Research output: Contribution to journalArticle

Bizzarri, Mariano ; Cucina, Alessandra ; Valente, Maria Giovanna ; Tagliaferri, Fausto ; Borrelli, Valeria ; Stipa, Francesco ; Cavallaro, Antonino. / Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures. In: Journal of Surgical Research. 2003 ; Vol. 110, No. 2. pp. 332-337.
@article{7ad7aa23b4b4451ab389bbf37a26c500,
title = "Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures",
abstract = "Background. Evidence has accumulated that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is involved in the regulation of the proliferation of breast tumor cells. For complete tumor suppression high hypercalcemic doses of 1,25-(OH)2D3 are needed. The aim of this study was to assess the effect of combined treatment of 1,25-(OH)2D3 at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4. Materials and methods. RM4 cell proliferation was assessed by [3H]thymidine uptake. The presence of TGF-β1 in serum-free conditioned medium was determined by inhibition antibody binding assay. Results. In 17-βE cultured RM4 cells both MEL and 1,25-(OH)2D3 alone and in combination significantly reduced [3H]thymidine incorporation in a dose-related fashion. MEL by itself was ineffective in inhibiting the FCS-cultured RM4 cells, while 1,25-(OH)2D3 strongly inhibited [3H]thymidine incorporation. Meanwhile, MEL increased the sensitivity of the FCS-cultured RM4 cells to 1,25-(OH)2D3 in the combined regimen, from 20- to 100-fold. MEL significantly enhanced the TGF-β1 secretion from RM4 cells and vitamin D3 increased the TGF-β1 secretion in a dose-dependent manner, from 2- to 7-fold. Moreover, a further enhancement of the TGF-β1 release was obtained with the combined treatment, but only for low 1,25-(OH)2D3 concentrations. The addition of monoclonal anti-TGF-β1 antibody to the medium of RM4 cells exposed to vitamin D3 alone or in combination with MEL increased the [3H]thymidine uptake compared to the correspondent cells cultured without antibody. Conclusions. Our data point to a potential benefit of combination therapy with 1,25-(OH)2D3 and MEL in the treatment of breast cancer and suggest that the growth inhibition could be related, at least in part, to the enhanced TGF-β1 secretion.",
keywords = "Breast cancer, Melatonin, TGF-β, Vitamin D",
author = "Mariano Bizzarri and Alessandra Cucina and Valente, {Maria Giovanna} and Fausto Tagliaferri and Valeria Borrelli and Francesco Stipa and Antonino Cavallaro",
year = "2003",
month = "4",
doi = "10.1016/S0022-4804(03)00040-4",
language = "English",
volume = "110",
pages = "332--337",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Melatonin and vitamin D3 increase TGF-β1 release and induce growth inhibition in breast cancer cell cultures

AU - Bizzarri, Mariano

AU - Cucina, Alessandra

AU - Valente, Maria Giovanna

AU - Tagliaferri, Fausto

AU - Borrelli, Valeria

AU - Stipa, Francesco

AU - Cavallaro, Antonino

PY - 2003/4

Y1 - 2003/4

N2 - Background. Evidence has accumulated that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is involved in the regulation of the proliferation of breast tumor cells. For complete tumor suppression high hypercalcemic doses of 1,25-(OH)2D3 are needed. The aim of this study was to assess the effect of combined treatment of 1,25-(OH)2D3 at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4. Materials and methods. RM4 cell proliferation was assessed by [3H]thymidine uptake. The presence of TGF-β1 in serum-free conditioned medium was determined by inhibition antibody binding assay. Results. In 17-βE cultured RM4 cells both MEL and 1,25-(OH)2D3 alone and in combination significantly reduced [3H]thymidine incorporation in a dose-related fashion. MEL by itself was ineffective in inhibiting the FCS-cultured RM4 cells, while 1,25-(OH)2D3 strongly inhibited [3H]thymidine incorporation. Meanwhile, MEL increased the sensitivity of the FCS-cultured RM4 cells to 1,25-(OH)2D3 in the combined regimen, from 20- to 100-fold. MEL significantly enhanced the TGF-β1 secretion from RM4 cells and vitamin D3 increased the TGF-β1 secretion in a dose-dependent manner, from 2- to 7-fold. Moreover, a further enhancement of the TGF-β1 release was obtained with the combined treatment, but only for low 1,25-(OH)2D3 concentrations. The addition of monoclonal anti-TGF-β1 antibody to the medium of RM4 cells exposed to vitamin D3 alone or in combination with MEL increased the [3H]thymidine uptake compared to the correspondent cells cultured without antibody. Conclusions. Our data point to a potential benefit of combination therapy with 1,25-(OH)2D3 and MEL in the treatment of breast cancer and suggest that the growth inhibition could be related, at least in part, to the enhanced TGF-β1 secretion.

AB - Background. Evidence has accumulated that 1,25-dihydroxyvitamin D3 [1,25-(OH)2D3] is involved in the regulation of the proliferation of breast tumor cells. For complete tumor suppression high hypercalcemic doses of 1,25-(OH)2D3 are needed. The aim of this study was to assess the effect of combined treatment of 1,25-(OH)2D3 at low doses and melatonin (MEL) on the proliferation of estrogen-responsive rat breast cancer cell line RM4. Materials and methods. RM4 cell proliferation was assessed by [3H]thymidine uptake. The presence of TGF-β1 in serum-free conditioned medium was determined by inhibition antibody binding assay. Results. In 17-βE cultured RM4 cells both MEL and 1,25-(OH)2D3 alone and in combination significantly reduced [3H]thymidine incorporation in a dose-related fashion. MEL by itself was ineffective in inhibiting the FCS-cultured RM4 cells, while 1,25-(OH)2D3 strongly inhibited [3H]thymidine incorporation. Meanwhile, MEL increased the sensitivity of the FCS-cultured RM4 cells to 1,25-(OH)2D3 in the combined regimen, from 20- to 100-fold. MEL significantly enhanced the TGF-β1 secretion from RM4 cells and vitamin D3 increased the TGF-β1 secretion in a dose-dependent manner, from 2- to 7-fold. Moreover, a further enhancement of the TGF-β1 release was obtained with the combined treatment, but only for low 1,25-(OH)2D3 concentrations. The addition of monoclonal anti-TGF-β1 antibody to the medium of RM4 cells exposed to vitamin D3 alone or in combination with MEL increased the [3H]thymidine uptake compared to the correspondent cells cultured without antibody. Conclusions. Our data point to a potential benefit of combination therapy with 1,25-(OH)2D3 and MEL in the treatment of breast cancer and suggest that the growth inhibition could be related, at least in part, to the enhanced TGF-β1 secretion.

KW - Breast cancer

KW - Melatonin

KW - TGF-β

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=0038209091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038209091&partnerID=8YFLogxK

U2 - 10.1016/S0022-4804(03)00040-4

DO - 10.1016/S0022-4804(03)00040-4

M3 - Article

C2 - 12788662

AN - SCOPUS:0038209091

VL - 110

SP - 332

EP - 337

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -